Cardiac arrest results in rapid decline of myocardial tissue oxygen tension, leading to general cellular anoxia and the initiation of cell death within minutes. The treatment guidelines for cardiac arrest entails immediate intervention designed to generate blood flow, while the underlying causal factors of the arrest are identified and treated.

Standard cardiopulmonary resuscitation protocols, however, produce only about 25% of necessary cardiac output, even when optimally performed. Furthermore, the quality of cardiopulmonary resuscitation during both out-of-hospital and inpatient cardiac arrest (IHCA) in adults has proven to be non optimal in terms of the recommended frequency, depth and minimum interruption of compression (1).

Rescue Code has designed a novel protocol for treating patients who have undergone cardiac arrest. The patented protocol yields results far superior than the current state of the art and is expected to save many patients’ lives.

About us

The R-Code (Rescue Code) offers cutting-edge technologies in the field of cardiac surgery, emergency cardiac surgery and interventional cardiology.

Our technologies are rooted in decades of multidisciplinary R&D on the advanced clinical approaches in the rescue and treatment of patients at risk of imminent death. The optimization of theses multidisciplinary clinical pathways have significantly improved mortality rates and the overall clinical consequences of cardiac arrest or cardiogenic shock after severe acute myocardial infarction.

The core of R-Code lies in the execution of an innovative protocol, including diagnostic and therapeutic care pathways that enable the activation of a multidisciplinary rescue team for the treatment of emergency infarcted patients (with cardiac arrest and refractory cardiogenic shock), including the training of personnel specialized in emergency therapy.

Cardiac arrest is a cardiological emergency that is burdened by a very high mortality rate, which can reach 100% in refractory cases (Source: University Hospital Foundation Agostino Gemelli IRCSS) despite conventional treatments (Cardio Pulmonary Resuscitation, advanced CPR). Cardiogenic shock, on the other hand, is a medical emergency caused by an alteration in cardiac function, with reduced peripheral perfusion associated with cellular dysfunction, and is characterized by a mortality of 50% (Source: Agostino Gemelli University Hospital Foundation IRCSS).

R-Code’s revolutionary innovation, which entails the activation of a multidisciplinary rescue team within an ambulance specially equipped with the necessary equipment, has been tested and validated by a center of excellence in the sector. Composed of anesthesiologists, cardiac surgeons, cardiologists, perfusionists and resuscitators, the rescue team is trained in the execution of the protocol for the treatment of “refractory” cardiac arrest. When the heart does not restart after the conventional cardio-pulmonary resuscitation maneuvers encoded by the “chain of survival”, the R-Code protocol is activated.


This innovative protocol is a scientifically validated therapeutic assistance pathway for intervention during refractory cardiac arrest,i.e. when the heart does not “restart” following implementation of conventional cardiopulmonary resuscitation maneuvers as set forth by the “chain of survival “.

R-Code offers an advanced care solution for patients affected by serious cardiac events, where complex therapies such as miniaturized extracorporeal circulation and therapeutic hypothermia, are implemented by an expert multidisciplinary aid team, consisting of anesthesiologists, cardiac surgeons, cardiologists, perfusionists and resuscitators..

Clinical work and scientific studies have demonstrated that the R Code multidisciplinary method for the advanced treatment of refractory cardiac arrest significantly increases survival chances of patients. The members of the R-Code project are ready in an ambulance duly equipped to activate the protocols, along with a multidisciplinary team specialized in maintaining the perfusion of the organs. The team instantly places the patient in ECMO (Extra Corporeal Membrane Oxygenation), which is carried out by cannulating the main blood vessels, i.e. arteries and veins. The body temperature is then lowered to state of hypothermia, since this state protects the organs from ischemia that can result from the total absence of blood supply.

Protocol of diagnostic therapeutic assistance pathway

The R Code solution includes two different applications of the same technology:

  • one is implemented inside the hospital first aid department
  • the second one is a mobile version of the same technology (ambulance). In just a few minutes it is possible to bring together a multidisciplinary specialist team. The patient is kept alive thanks to an instrument that has the function of an external artificial heart and lung; a state of hypothermia is induced, a controlled hibernation with which brain cells are preserved. At the same time, specialists can diagnose and intervene in the cause of cardiac arrest. Once the crisis is over, the patient is gradually brought back to normothermia in the process of “resuscitation”.

The second solution is a combination of a hydro- dissector with a standard mono-polar electrical scalpel. The hydro dissector is driven by a fluid which is a combination of sterile water and carbon dioxide. It is used to separate delicate tissues and cool down scalpel tip. The technology increases visibility during surgery. The technology  represents an instrumental evolution in the field of cardiology and cardiac surgery, eliminating the side effect of carbonization of tissues typical of this class of instruments.

TARGET MARKET: The company, through its technologies targets the following markets:

  • The cardio-surgery market: this market shows a TAM of 1.7b USD and projects a CAGR of 3.2% on average until 2023
  • The Cardiac Arrest market: this market shows a TAM of 2.7b USD and projects a CAGR of 4.4% on average until 2024